BRCA1 and neoplasm: Studies reveal that tumor cells with BRCA1/2 deficiencies exhibit high sensitivity to PARP inhibitors, a phenomenon termed “synthetic lethality,” meaning that inhibiting PARP in a BRCA-deficient background results in tumor cell death (51).